Iressa Approval Would Set Bad Precedent For Oncology, Genta CEO Tells BIO
Executive Summary
FDA's decision about AstraZeneca's pending oncologic Iressa will send a "strong message" to industry about whether the agency is serious about high approval standards for cancer drugs, Genta CEO Ray Warrell, MD, said Feb. 26 during the Biotechnology Industry Organization CEO and investor conference in New York
You may also be interested in...
Iressa Gets Narrowed Indication Instead Of Withdrawal: New Model For FDA?
FDA's decision to narrow the indication for AstraZeneca's Iressa rather than withdraw the drug could be seen as a model for future products approved under Subpart H that fail in confirmatory trials
Iressa Gets Narrowed Indication Instead Of Withdrawal: New Model For FDA?
FDA's decision to narrow the indication for AstraZeneca's Iressa rather than withdraw the drug could be seen as a model for future products approved under Subpart H that fail in confirmatory trials
Iressa To The Rescue: Oncology Stocks Stand Out On Wall Street
Millennium's multiple myeloma agent Velcade is leading the parade of oncologic therapies attracting renewed enthusiasms from investors